KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Assets (2017 - 2025)

Historic Assets for Moderna (MRNA) over the last 9 years, with Q3 2025 value amounting to $12.1 billion.

  • Moderna's Assets fell 2321.08% to $12.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 billion, marking a year-over-year decrease of 2321.08%. This contributed to the annual value of $14.1 billion for FY2024, which is 2324.98% down from last year.
  • As of Q3 2025, Moderna's Assets stood at $12.1 billion, which was down 2321.08% from $12.0 billion recorded in Q2 2025.
  • Moderna's Assets' 5-year high stood at $27.6 billion during Q1 2022, with a 5-year trough of $12.0 billion in Q2 2025.
  • In the last 5 years, Moderna's Assets had a median value of $18.4 billion in 2023 and averaged $19.1 billion.
  • As far as peak fluctuations go, Moderna's Assets surged by 51396.61% in 2021, and later crashed by 3065.7% in 2024.
  • Moderna's Assets (Quarter) stood at $24.7 billion in 2021, then increased by 4.82% to $25.9 billion in 2022, then decreased by 28.74% to $18.4 billion in 2023, then decreased by 23.25% to $14.1 billion in 2024, then dropped by 14.19% to $12.1 billion in 2025.
  • Its last three reported values are $12.1 billion in Q3 2025, $12.0 billion for Q2 2025, and $12.7 billion during Q1 2025.